June 23, 2024
1 min watch
Save
VIDEO: Annexon previews emerging data on ANX007 for geographic atrophy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Lori Taylor of Annexon Biosciences previews data on ANX007 for the treatment of geographic atrophy.
The data focus on the preservation of photoreceptors and retinal pigment epithelial cells in the foveal center.
“This mechanism likely makes sense, preserving retinal structure in places that matter to visual acuity, and may explain why we see the visual acuity benefit with ANX007,” she said.
Published by:
Sources/Disclosures
Collapse
Source:
Jaffe G. Regional effects of ANX007 on RPE and photoreceptor loss and relationship to visual acuity in ARCHER phase 2 trial. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.
Disclosures:
Taylor reports being the senior vice president for portfolio strategy and operations at Annexon Biosciences.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.